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Uses and misuses of definitions of genetic polymorphism. A 
perspective from population pharmacogenetics 
Definitions of genetic polymorphism currently employed 
in the pharmacological literature have been incorrectly 
used (Kalow, 1984) and uncritically imported from 
population genetics [e.g., Weinshilboum (1984), Evans 
(1977)], apparently without regard to the problems their 
application might present in pharmacogenetics or, more 
specifically, in pharmacogenetic studies of populations. 
Since a strong background in population genetics is 
not widespread amongst population pharmacogeneticists 
and especially amongst pharmacologists, there is a 
growing danger that these definitions will be misinter-
preted or incorrectly used, as research on potentially 
polymorphic biotransformation routes increases. 
The term polymorphism was first defined by E. B. 
Ford who stated that 
. . Polymorphism may be defined as the occurrence 
together in the same habitat of two or more dis-
continuous forms of a species in such proportions 
that the rarest of them cannot be maintained merely 
by recurrent mutation . . (Ford, 1940, 1965). 
Ford, in fact, was referring to morphological character-
istics, mostly those of butterflies (Lewontin, 1974). 
The emphasis on phenotypic traits as a criterion for 
polymorphism is again reflected in the definition pro-
posed by Vogel and Motulsky, who state: 
. . A polymorphism is a Mendelian or monogenic 
trait that exists in the population in at least two 
phenotypes (and presumably at least two genotypes), 
neither of which is rare—that is, neither of which 
occurs with a frequency of less than 1-2% . . . 
A polymorphism should be contrasted with a rare 
genetic variant. Rare genetic variants are arbitrarily 
defined as monogenic traits that occur in the population 
with a frequency of less than 1-2% and usually at 
much lower frequencies.' (Vogel & Motulsky, 1986). 
The essence of this definition is contained in the first 
of two earlier ones proposed by Cavalli-Sforza & Bodmer 
(1971) (Chapter 2, p. 41). In a later chapter of their 
book, these authors present an alternate set of definitions, 
which has been adopted by others, including the 
frequently cited Harris (1980) and, more recently, Crow 
(1986) and Nei (1987). They defined polymorphism in 
the following way: 
`Genetic polymorphism is the occurrence in the same 
population of two or more alleles at one locus, each 
with appreciable frequency.' 
They go on to affirm that . . The definition of "appreci-
able frequency" is arbitrary (our italics) . . .', and then 
declare that . . it can be taken to be of the order of 
one percent.' (Cavalli-Sforza & Bodmer, 1971, Chapter 
4, p. 118). 
It is evident from these definitions that there is still 
no common agreement, but rather a very fierce con-
troversy (Harris, 1980) about the evolutionary origin of 
polymorphisms and the forces which maintain them at 
specific frequency levels (Nei, 1987). As a consequence, 
all definitions of polymorphism used today are, as they 
ought to be, operative or working definitions since, 
starting from Cavalli-Sforza & Bodmer in 1971, they 
purposefully eschew any real theoretical underpinning. 
Hence, the differences between polymorphism and rare 
genetic variants are no longer explained by mechanistic 
arguments and are, therefore, necessarily and entirely 
arbitrary (Crow, 1986; Hartl, 1980; Hedrick, 1983; Nei, 
1987). 
According to the allelic definition of Harris (1980, 
p. 331), polymorphism exists when the . . commonest 
identifiable allele has a frequency no greater than 0.99 
. . 	 (P 0.99 or q 0.01). This signifies that, when 
the Hardy-Weinberg law applies (p2 + 2pq + q2) and 
when 1% is taken as the lower limit of frequency for the 
rarest allele, the distribution of phenotypes would result 
in 98.01% of homozygous individuals for the commonest 
allele, 1.98% of heterozygotes, and 0.01% (1 in 10,000 
subjects) of homozygotes for the least frequent allele. 
In the field of population pharmacogenetics, the main 
concern is the determination of phenotypes, because of 
the potential clinical implications arising from the large 
differences in metabolic activity between extensive and 
poor metabolizers, e.g., 20-fold in Caucasian sparteine 
oxidation. Furthermore, classical methodology (meta-
bolic phenotyping) does not permit, in most cases, the 
resolution of homozygotes dominant (the so-called 
extensive metabolizers) from the heterozygous subjects 
(Tucker et al., 1986) or the unambiguous identification 
of phenotypes with genotypes (Steiner et al., 1985). 
This is valid even when the most up-to-date DNA probe 
studies are conducted (Idle, 1989). A further point in 
favour of the identification of phenotypes arises from 
the potential dissociation between phenotype and geno-
type, as might be the case in certain races (Yue et al., 
1989). 
The desire to determine phenotypic status coupled 
with the common inability to detect genotypes directly, 
resulted in the universal adoption in the pharmacological 
literature of Cavalli-Sforza & Bodmer's (1971) and Vogel 
& Motulsky's (1986) phenotypic definitions for poly-
morphism. The only reasonable interpretation of these 
phenotypic definitions is that, if the number of poor 
metabolizers (presumably homozygotes recessive) 
corresponds to at least 1-2% of the total sample popula-
tion, genetic polymorphism exists. Inversely, if the 
number of poor metabolizers is below 1-2%, poly-
morphism is said not to be evident or its absence could 
have been implied (Arias et al., 1986; Eichelbaum & 
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Woolhouse, 1985; Iyun et al., 1986; Lou et al., 1987; 
Nakamura et al., 1985; Tucker et al., 1986; Woolhouse 
et al., 1985). 
This view is shared by all researchers in population 
pharmacogenetics who have claimed absence of evidence 
for the existence of polymorphism, and, presumably, 
by the editors and most of the reviewers of their 
publications. Had pharmacogeneticists explicitly 
adopted the newer allelic-based definition, exclusively 
employed in the last 20 years in population genetics, 
they would have had to face the practical impossibility 
of studying thousands of subjects before they could 
claim that polymorphism was absent. Population 
geneticists have not encountered this limitation ever 
since efficient electrophoretic and, to a lesser extent, 
ex vivo techniques have been available. They can easily 
search both for the least common homozygous subjects, 
as well as for the almost 200 times more numerous 
heterozygotes. As a result, population geneticists have 
usually only needed to study `. . . no more than a 
hundred or two . . .' unrelated subjects to be able to 
detect polymorphisms (Harris, 1980, p. 343). This 
explains why this number has pervaded pharmaco-
geneticists' circles as an incorrect first approximation 
to the desired sample size, given the usual impossibility 
of identifying heterozygotes. 
Pharmacogeneticists have failed to recognize that 
allelic and phenotypic definitions yield different estimates 
for phenotypes in a given population. It became evident 
to us —at least 3 years ago (Arias et al., 1988) — that, 
when the Hardy-Weinberg law was used to calculate 
phenotypic frequencies at the lower limits of the allelic 
and phenotypic definitions of polymorphism, there was 
an unacceptable discrepancy. For instance, in the pheno-
typic definition the least common phenotype (q2 
0.01) would show a frequency one hundred times larger 
than the value (q2 	 0.0001) which would result 
if Harris' allelic definition (q 	 0.01) were applied. 
Similarly, there is an approximate 10-fold difference in 
heterozygote frequency (2pq). 
While this paper was under review, we consulted 
with one of the authors of the most commonly used 
phenotypic definitions (A. Motulsky), who indicated 
the following (November, 1988): 
`. . . We (Vogel/Motulsky) may have contributed to 
the confusion by not expanding our definition of 
polymorphisms to indicate that we did not mean 
homozygotes when referring to a phenotype frequency 
of more than 1-2% . . . the Harris definition (q or 
allele frequency > 0.01-0.02) is similar to the Vogel-
Motulsky definition which implies 2q or heterozygote 
frequency > 0.01-0.02 or q > 0.005-0.01 . . 
Motulsky's overdue clarification makes it now 
necessary for pharmacogeneticists to abandon their 
phenotypic interpretation of Vogel & Motulsky's (1986) 
definition of polymorphism and search for an adequate 
definition. 
For the reasons stated above, we are of the opinion 
that, in pharmacogenetics, definitions of polymorphisms 
must be explicitly based on phenotypic grounds, with 
a 1% frequency of the least common phenotype as the 
lower limit. This value is as arbitrary as any other ever 
used in population genetics (Cavalli-Sforza & Bodmer, 
1971; Crow, 1986; Harris, 1980; Hartl, 1980; Hedrick, 
1983; Nei, 1987); but it best lends itself to the interests 
and possibilities of our discipline. 
In order to avoid contradictions between pharmaco-
genetic usage and genetic theory and concepts, we 
further propose that the polymorphisms thus character-
ized be referred to as `pharmacogenetic polymorphisms'. 
The essential nature of these polymorphisms was recog-
nized by Harris (1980, p. 340) when he described them 
as `. . . "quantitative" enzyme polymorphisms . . 
They would be defined in terms of phenotypic fre-
quencies, with a lower limit of 1% , and would be 
characteristic of metabolic inborn errors of pharmaco-
logic relevance. This new definition would not require 
unambiguous identification of genotypes with pheno-
types and some other Hardy-Weinberg conditions for 
its application, such as equilibrium. The latter feature 
would allow its use in populations which deviate from 
these characteristics, e.g., Amerindian groups and other 
genetic isolates. 
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Phenotype or genotype? 
The term polymorphism means literally 'many shapes 
or forms'. In biology, polymorphism was used origi-
nally with respect to morphology but is now applied to 
any biological characteristic. In population studies 
polymorphisms are determined operationally by 
inspection of the frequency distribution of the trait in 
question. Any discontinuity in the distribution curve 
could legitimately be said to demonstrate the existence 
of a polymorphism. Although the underlying basis of 
such a polymorphism may be genetic, this is not 
necessarily so. Thus, strictly speaking, those poly-
morphisms with a genetic basis should be described as 
genetic polymorphisms, although the term poly-
morphism is now widely used in this sense. 
Pharmacogeneticists may be divided into those who 
wish to use (genetic) polymorphisms as anthropological 
tools and those interested in their possible clinical 
relevance in interindividual variability in drug meta-
bolism. The former group often wish to define differ-
ences in genotype between populations, whilst the 
latter are primarily interested in determining 
differences in phenotype between individuals. The 
difference between these aims is reflected in the way in 
which a polymorphism is described. Thus, the defini- 
tion may be couched either in terms of the genotype, 
based on the frequency of the less common allele, or in 
terms of the phenotype, based on the frequency of the 
least common phenotype. This is not just a question of 
semantics, but has important implications for all areas 
of pharmacogenetics. In their letter, Professor Arias 
and his colleagues (1991) point out the confusion which 
has arisen from the indiscriminate use of these alter-
native, but not interchangeable, definitions, and argue 
in favour of the 'phenotype' definition largely because 
they consider it easier to implement. They indicate that 
the early definition of a (genetic) polymorphism, 
devised by population geneticists, was based on phen-
otype, but it is perhaps not surprising that this definition 
has 'evolved' as the science of genetics has progressed. 
Thus, when the only means of determining genotype 
was by breeding experiments, the phenotype was 
commonly used as the unit of genetic variation. Now, 
when it is possible to determine genotype directly, the 
allele has become the unit preferred by population 
geneticists. Whilst the mechanistic distinction between 
polymorphisms and rare genetic traits is unclear, the 
exact value of the frequency of occurrence of the least 
common genetic variant must remain arbitrary. 
